Truvada to prevent HIV infection
The CDC is now recommending Truvada (emtricitabine and tenofir) daily to prevent HIV infection in high-risk adults. In a new guideline titled “Preexposure Prophylaxis for the Prevention of HIV Infection in the United States – 2014),” experts from the CDC define at-risk individuals who are candidates for pre-exposure prophylaxis. This includes men who have sex with men who are not in a monogamous relationship and who engage in unprotected anal intercourse, heterosexually active adults with multiple partners who do not use condoms on a regular basis, any adult in an ongoing relationship with an HIV-positive partner, injection drug users who share needles or who are at risk of sexual acquisition of HIV, and others. The dose of Truvada is one pill a day — the same dose given to treat HIV infection in adults. Patients on prophylaxis should be HIV negative before starting the drug and should be tested every 3 months. The recommendation is based on several studies, including international studies that were done on at-risk populations such as all the risk groups mentioned above, which showed that the drug can reduce the rate of HIV infection by more than 90%. Truvada costs about $15,000 per year. The drug is manufactured by Gilead Sciences — the same company that makes the hepatitis C drug sofosbuvir.
Subscribe Now for Access
You have reached your article limit for the month. We hope you found our articles both enjoyable and insightful. For information on new subscriptions, product trials, alternative billing arrangements or group and site discounts please call 800-688-2421. We look forward to having you as a long-term member of the Relias Media community.